Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Exact Sciences

Abbott Stock Crash: Rebound Could Be Coming Fast

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

MarketBeat

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

MarketBeat

My Top 10 Stock Picks for 2026

Each year, we ask an expert to pick 10 stocks that have the potential to beat the market over the next 12 months. Here are his choices for 2026.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Barchart

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

International Business Times UK

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga

Top 3 Health Care Stocks That Are Preparing To Pump This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Benzinga

What 19 Analyst Ratings Have To Say About Exact Sciences

19 analysts have shared their evaluations of Exact Sciences (NASDAQ:EXAS) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga

1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA Win

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Barchart

Cologuard Classic: Golf Tournament Promotes Colon Cancer Awareness And Advocacy

The Cologuard Classic combines golf and advocacy to raise awareness about colon cancer screening, featuring top players and supporting survivors.

Top News

1 Cathie Wood Stock with 65% Upside Potential

This stock holds a spot in maverick investor Wood's flagship fund, and analysts agree the cutting-edge diagnostics specialist has plenty of growth potential from current levels.

Barchart

3 Cathie Wood Stocks Beating the Nasdaq This Year

The maverick fund manager catches a lot of heat for her stock picks, but these three ARKK standouts are absolutely crushing the broader Nasdaq Composite so far in 2023.

Barchart

Moderation in U.S. Consumer Prices Boost Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.11%. Stock indexes Wednesday settled mixed, with the S&P 500...

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Markets Today: Stocks Rally as U.S. CPI Eases

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.37%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.45%. U.S. stock index futures this morning erased overnight losses and pushed higher after U.S. consumer prices eased in April. Bond yields also fell on the...

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022

Upgrades

Axios

Next-gen blood tests to detect cancer and other diseases come with questions

The tests can help detect some diseases early but it's still unclear how much they affect whether someone survives a disease.

Benzinga

Expert Ratings for Exact Sciences

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Preview: Exact Sciences's Earnings

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.07.

Benzinga

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.